White Blood Cell Count Predicts All-Cause Mortality in Patients with Suspected Peripheral Arterial Disease

American Journal of Medicine

Volumn 122, Issue 9, 2009, Pages

  Arain, Faisal A ^a   Khaleghi, Mahyar ^a   Bailey, Kent R ^a   Lahr, Brian D ^a   Rooke, Thom W ^a   Kullo, Iftikhar J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Pathophysiology; Peripheral vascular disease; Risk factors

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; CREATININE;

ADULT; AGED; ANAMNESIS; ARTERY DISEASE; ARTICLE; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MORTALITY; PRIORITY JOURNAL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; C-REACTIVE PROTEIN; CAUSE OF DEATH; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; PERIPHERAL VASCULAR DISEASES; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 68749095877     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.02.020     Document Type: Article

References (28)

1. Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
2. Criqui M.H., Langer R.D., Fronek A., et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326 (1992) 381-386
3. Steg P.G., Bhatt D.L., Wilson P.W.F., et al., Investigators R.R. One-year cardiovascular event rates in outpatients with atherothrombosis. [see comment]. JAMA 297 (2007) 1197-1206
4. Grundy S.M., Cleeman J.I., Merz C.N.B., et al., National Heart LaBI, American College of Cardiology F, American Heart A. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. [erratum appears in Circulation. 2004 Aug 10;110(6):763]. Circulation 110 (2004) 227-239
5. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
6. Ridker P.M., Stampfer M.J., and Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. [see comment]. JAMA 285 (2001) 2481-2485
7. Wildman R.P., Muntner P., Chen J., et al. Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999-2002. Am J Cardiol 96 (2005) 1579-1583
8. Garza C.A., Montori V.M., McConnell J.P., et al. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. [see comment]. Mayo Clin Proc 82 (2007) 159-165
9. Rossi E., Biasucci L.M., Citterio F., et al. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation 105 (2002) 800-803
10. Haim M., Boyko V., Goldbourt U., et al. Predictive value of elevated white blood cell count in patients with preexisting coronary heart disease: the Bezafibrate Infarction Prevention Study. Arch Intern Med 164 (2004) 433-439
11. Grau A.J., Boddy A.W., Dukovic D.A., et al., for the C.I. Leukocyte Count as an Independent Predictor of Recurrent Ischemic Events. Stroke 35 (2004) 1147-1152
12. Haumer M., Amighi J., Exner M., et al. Association of neutrophils and future cardiovascular events in patients with peripheral artery disease. J Vasc Surg 41 (2005) 610-617
13. Vidula H., Tian L., Liu K., et al. Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. Ann Intern Med 148 (2008) 85-93
14. Hirsch A.T., Criqui M.H., Treat-Jacobson D., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. [see comment]. JAMA 286 (2001) 1317-1324
15. Santos S., Rooke T.W., Bailey K.R., et al. Relation of markers of inflammation (C-reactive protein, white blood cell count, and lipoprotein-associated phospholipase A2) to the ankle-brachial index. Vasc Med 9 (2004) 171-176
16. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006) 251-259
17. Pencina M.J., D'Agostino Sr. R.B., D'Agostino Jr. R.B., and Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. [see comment]. Stat Med 27 (2008) 157-172 discussion 207-112
18. Kim W.R., Biggins S.W., Kremers W.K., et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 359 (2008) 1018-1026
19. Khawaja F.J., Bailey K.R., Turner S.T., et al. Association of novel risk factors with the ankle brachial index in African American and non-Hispanic white populations. Mayo Clin Proc 82 (2007) 709-716
20. Nasir K., Guallar E., Navas-Acien A., et al. Relationship of monocyte count and peripheral arterial disease: results from the National Health and Nutrition Examination Survey 1999-2002. Arterioscler Thromb Vasc Biol 25 (2005) 1966-1971
21. Vainas T., Stassen F.R.M., de Graaf R., et al. C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events. J Vasc Surg 42 (2005) 243-251
22. Coller B.S. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene?. Arterioscler Thromb Vasc Biol 25 (2005) 658-670
23. Madjid M., Awan I., Willerson J.T., and Casscells S.W. Leukocyte count and coronary heart disease: Implications for risk assessment. J Am Coll Cardiol 44 (2004) 1945-1956
24. Wilson A.M., Ryan M.C., and Boyle A.J. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol 106 (2006) 291-297
25. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. [see comment]. Circulation 105 (2002) 1135-1143
26. Beckman J.A., Preis O., Ridker P.M., and Gerhard-Herman M. Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death). Am J Cardiol 96 (2005) 1374-1378
27. Allison M.A., Denenberg J.O., Nelson J.J., et al. The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients. J Vasc Surg 46 (2007) 500-506
28. Greenland P., and O'Malley P.G. When is a new prediction marker useful?. A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk. [comment]. Arch Intern Med 165 (2005) 2454-2456